文献速递关节外科

肥胖与慢性阿片类药物使用未负向影响全髋关节置换术后达到CMS规定的HOOS JR评分阈值

Obesity and Chronic Opioids Were Not Negatively Associated With Achieving Centers for Medicare and Medicaid Services Mandated Thresholds for Hip Disability and Osteoarthritis Outcome Score for Joint Replacement Scores After Primary Total Hip Arthroplasty.
PubMed 文献 · J Arthroplasty · 2026-06-17

本研究回顾性分析1682例初次全髋关节置换术,评估基于CMS规定的HOOS JR改善阈值(22分)的预测因素。平均随访22个月,76.8%患者达到22分阈值,94.5%达到6.0分最小临床重要差异。多变量分析显示仅BMI增加与更大HOOS JR改善相关(P=0.006),慢性阿片类药物使用与达到阈值或改善评分无关(P≥0.336)。

要点

  • 肥胖(BMI增加)与更大的HOOS JR评分改善相关,未负向影响达标。
  • 术前慢性阿片类药物使用与HOOS JR阈值达标或改善评分无关。
  • 76.8%患者达到CMS 22分substantial clinical benefit阈值。

核心结论

  • 肥胖和术前慢性阿片类药物使用未负向影响全髋关节置换术后达到CMS规定的HOOS JR改善评分阈值。
  • 所收集变量中极少患者特征对CMS 22分HOOS JR改善阈值有强区分能力。

研究设计与样本

  • 单外科医生回顾性队列研究,连续纳入1682例初次全髋关节置换术。
  • 从全州医疗系统手动提取患者数据,包括纤维肌痛、自身免疫病、骨坏死、抑郁、慢性麻醉药品使用和腰椎疾病。
  • 采用多变量统计分析,P<0.05为统计学显著。

主要发现

  • 平均临床随访22个月,HOOS JR评分较术前基线平均改善36.0分(范围-44至100)。
  • 76.8%患者达到CMS建议的22分substantial clinical benefit阈值,94.5%达到6.0分最小临床重要差异阈值。
  • 多变量分析中,仅BMI增加与更大HOOS JR评分改善相关(P=0.006)。
  • 慢性麻醉药品使用与达到HOOS JR阈值或改善评分无关(P≥0.336,统计效力≥91.6%)。

关键数值与推荐

  • CMS规定的HOOS JR改善阈值为22分(substantial clinical benefit)。
  • 最小临床重要差异阈值为6.0分。
  • 统计显著性设定为P<0.05。

临床怎么用

  • 基于本研究,不应仅因肥胖或术前慢性阿片类药物使用而回避全髋关节置换术患者。
  • CMS将于2026年开始强制要求HOOS JR改善阈值,医生和机构数据将公开报告。

局限性

  • 单外科医生回顾性队列研究,证据等级III。
  • 研究仅纳入所收集变量,其他未测量因素可能影响结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The Centers for Medicare and Medicaid Services (CMS) will begin mandating Hip Disability and Osteoarthritis Outcome Score, Joint Replacement (HOOS JR) improvement thresholds for total hip arthroplasty (THA) starting in 2026 and have established a 22-point improvement target. Surgeon and institutional data will be publicly reported, and some may avoid patients who have risk factors for poor outcomes such as chronic opioid use. The purpose of this study was to identify predictors of HOOS JR improvement based on the CMS-mandated HOOS JR improvement threshold. METHODS: A total of 1,682 consecutive primary THAs were retrospectively reviewed. Patient data, including the presence of fibromyalgia, autoimmune disease, osteonecrosis, depression, chronic narcotic usage, and lumbar spine disease were manually extracted from a statewide health care system. Predictors of improvement in HOOS JR total scores were evaluated accounting for the minimal clinically important difference and substantial clinical benefit thresholds established by CMS. Multivariable statistical analyses were performed with P < 0.05 indicating statistical significance. RESULTS: At a mean clinical follow-up of 22 months, mean improvement in HOOS JR score from preoperative baseline was 36.0 points (range, -44 to 100). A total of 76.8% of patients met the HOOS JR substantial clinical benefit of 22 suggested by CMS, and 94.5% met the minimal clinically important difference threshold of 6.0. In multivariable analysis, only increasing body mass index was associated with greater improvement in HOOS JR scores (P = 0.006). Interestingly, chronic narcotic use was not associated with achieving HOOS JR thresholds or improvement scores (P ≥ 0.336, statistical power ≥ 91.6%). CONCLUSIONS: In this single-surgeon retrospective cohort, obesity and preoperative chronic opioid use were not negatively associated with achievement of HOOS JR improvement score thresholds. Furthermore, with the variables collected in this study, very few patient characteristics demonstrated strong discriminatory ability for the CMS 22-point HOOS JR improvement threshold. LEVEL OF EVIDENCE: III.

来源:J Arthroplasty,查看原文。版权归原作者所有。

引用

  1. Buller LT, Luo TD, Deckard ER, et al. Obesity and Chronic Opioids Were Not Negatively Associated With Achieving Centers for Medicare and Medicaid Services Mandated Thresholds for Hip Disability and Osteoarthritis Outcome Score for Joint Replacement Scores After Primary Total Hip Arthroplasty. J Arthroplasty. 2026. PMID: 42309399. doi:10.1016/j.arth.2026.06.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。